Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-03-19 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
北京德恒（昆明）律师事务所关于昆明药集团股份有限公司回购股份事宜的法律意见
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion issued by a law firm regarding a company's share repurchase (buyback) plan. It discusses the legal compliance, procedures, and conditions related to the company's repurchase of its own shares, including references to relevant laws and regulations, board and shareholder approvals, and disclosure obligations. The document does not contain financial statements or earnings data but focuses on the legality and procedural aspects of the share repurchase. This matches the description of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2018-03-19 Chinese
关于召开“昆药集团股份有限公司2015年公司债券”2018年度第二次债券持有人会议的通知
Capital/Financing Update Classification · 95% confidence The document is a detailed notice about convening a bondholders' meeting for the 2015 company bonds issued by Kunming Pharmaceutical Group Co., Ltd. It includes information about the meeting agenda, voting procedures, and related attachments such as the proposal for not requiring early repayment of the bonds due to stock repurchase and capital changes. The document is not a financial report, earnings release, or audit report. It is a formal notification to bondholders about a meeting and voting on bond-related matters, which fits the category of a Capital/Financing Update (CAP) because it relates to bondholder meetings and decisions affecting the company's debt and capital structure. The document length is sufficient and contains substantive content about the meeting and voting process, not just an announcement of a report publication. Therefore, the best classification is CAP with high confidence.
2018-03-15 Chinese
2018年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2018 second extraordinary shareholders' meeting of Kunming Pharmaceutical Corporation. It includes voting results on various proposals related to share repurchase, attendance details, legal witness statements, and confirmation of the meeting's legality and validity. The document is relatively short (3400 characters) and focuses on the official voting results and meeting details rather than presenting a full report or financial statements. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA).
2018-03-12 Chinese
2018年第二次临时股东大会的法律意见
Regulatory Filings Classification · 95% confidence The document is a legal opinion from a law firm regarding the convening, attendance, and voting procedures of a specific shareholders' meeting (the 2018 second extraordinary general meeting) of Kunming Pharmaceutical Group Co., Ltd. It details the legality and validity of the meeting and the resolutions passed, specifically about a share repurchase proposal. The document does not contain financial statements or detailed financial data, nor is it a report or announcement of financial results. It is not a proxy solicitation or voting results announcement but a legal opinion on the meeting's compliance. This type of document fits best under Regulatory Filings (RNS) as it is a compliance/legal opinion related to a corporate event but does not fit other more specific categories.
2018-03-12 Chinese
关于回购公司股份的债权人通知公告
Transaction in Own Shares Classification · 95% confidence The document is a notification announcement regarding the company's plan to repurchase its own shares, including details about the repurchase plan, financial data, and instructions for creditors to submit claims. It is not a financial report or earnings release but an official announcement about a share repurchase program. This fits the category of Transaction in Own Shares (POS). The document length is 1722 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is POS with high confidence.
2018-03-12 Chinese
关于前十名无限售条件股东情况的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the top ten unrestricted shareholders as of specific dates in 2018. It includes detailed tables of shareholders and their shareholdings, references to a share repurchase plan, and mentions a reduction in registered capital due to share cancellation. The document does not contain financial statements or detailed financial performance data. It primarily reports on shareholding structure and share repurchase plans, which aligns with disclosures about share ownership and capital changes. It is not a full financial report, earnings release, or management discussion. The content fits best with a Major Shareholding Notification (MRQ) because it details the top shareholders and changes in shareholdings, including share cancellation affecting total shares and ownership percentages. The document length is under 5,000 characters and is a direct announcement, not a report publication notice or certification. Therefore, the classification is MRQ with high confidence.
2018-03-08 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.